GLP-1 receptor agonists effectively manage glycemic control and weight loss in T2DM, and dual/triple incretin agonists targeting GLP-1, GIP, and Glucagon-receptor show promise but lack receptor-specific evaluations. The gene discussed is GIP; the disease is type 2 diabetes mellitus.